Posters

Outcomes of corneal cross-linking in ectasias other than keratoconus

Poster Details

First Author: K.Kawamoto UK

Co Author(s):    K. Kawamoto   T. Khanam                 

Abstract Details

Purpose:

Corneal cross-linking (CXL) has been successful in halting disease progression in keratoconus. Post-laser-assisted in situ keratomileusis (LASIK) ectasia and pellucid marginal degeneration are rarer causes of corneal ectasia, for which there is limited evidence on the efficacy of CXL. This study evaluates the long-term efficacy of CXL in post-LASIK ectasia and pellucid marginal degeneration.

Setting:

A retrospective review of patients who underwent CXL for post-LASIK ectasia and pellucid marginal degeneration over a five-year period in a tertiary hospital in London, UK (Moorfields Eye Hospital).

Methods:

15 patients (21 eyes; mean age 38 ± 6.5 years) had CXL between January 2014 and December 2018 with preoperative and 12-month postoperative outcome measures sufficient for analysis. Patients were subdivided into two groups, based on preoperative corneal thickness (< 400 and ≥ 400 micrometres) as this value represents the cut-off whereby CXL is contraindicated in keratoconus. Data were collected retrospectively from paper records and Pentacam reports. Comparison between preoperative and 12 months postoperative outcomes were made using paired samples T-test. Statistical analysis was performed using JASP Statistics 0.11.1.

Results:

For all parameters measured (best corrected visual acuity, thinnest location, Kmax, astigmatism, front K1 and front K2) there was no significant difference between preoperative and 12 months postoperative values, in both < 400 and ≥ 400 micrometre groups.

Conclusions:

We found there was not a statistically significant difference between pre-operative and 12 month, post-operative outcome measures. This was an expected outcome as CXL halts, rather than reverses disease progression. In our cohort, we had a small number of cases, as these conditions are rare. We also excluded a high number of cases (due to inadequate follow-up and missing Pentacam results). The findings highlight that CXL is an option for managing progressive PMD and post-refractive ectatic disorders.

Financial Disclosure:

None